Benitec Biopharma, Inc. (BNTC)
12.72
+0.04
(+0.35%)
USD |
NASDAQ |
Sep 08, 16:00
12.73
0.00 (0.00%)
Pre-Market: 20:00
Benitec Biopharma Net Income (Quarterly) : -11.94M for March 31, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -11.94M |
| December 31, 2025 | -11.84M |
| September 30, 2025 | -8.965M |
| June 30, 2025 | -8.805M |
| March 31, 2025 | -14.50M |
| December 31, 2024 | -9.552M |
| September 30, 2024 | -5.059M |
| June 30, 2024 | -4.72M |
| March 31, 2024 | -4.279M |
| December 31, 2023 | -6.798M |
| September 30, 2023 | -5.954M |
| June 30, 2023 | -4.661M |
| March 31, 2023 | -4.397M |
| December 31, 2022 | -5.411M |
| September 30, 2022 | -5.093M |
| June 30, 2022 | -5.067M |
| March 31, 2022 | -3.275M |
| December 31, 2021 | -4.821M |
| September 30, 2021 | -5.045M |
| June 30, 2021 | -4.003M |
| March 31, 2021 | -3.909M |
| Date | Value |
|---|---|
| December 31, 2020 | -3.252M |
| September 30, 2020 | -2.718M |
| June 30, 2020 | |
| March 31, 2020 | -2.102M |
| December 31, 2019 | -2.09M |
| September 30, 2019 | -1.147M |
| June 30, 2019 | -1.469M |
| March 31, 2019 | -1.704M |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | 0.5627M |
| June 30, 2016 | |
| March 31, 2016 | -1.769M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 11.94M |
| EPS Diluted (Quarterly) | -0.2417 |
| Enterprise Value | 253.16M |
| Earnings Yield | -7.30% |
| Normalized Earnings Yield | -7.301 |